A biologics license software for pivekimab sunirine (PVEK) has been submitted to the U.S. Meals and Drug Administration (FDA) for the therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a uncommon blood most cancers, in response to a information launch from AbbVie.
The submission for PVEK relies on outcomes from the worldwide section 1/2 CADENZA trial, which confirmed excessive and lasting remission charges in adults with BPDCN, in response to examine findings printed in Journal of Scientific Oncology. Remedy was usually tolerable, uncomfortable side effects had been manageable, and no capillary leak syndrome occurred.
The median follow-up was 21.5 months for sufferers receiving frontline therapy and 24.1 months for these with relapsed or refractory illness.
Amongst sufferers handled first-line, the mixed price of full remission and full remission with minimal pores and skin abnormality was 70%, and the median length of response for full remission and full remission with minimal pores and skin abnormality was 9.8 months. The general response price was 85%, and the median total survival was 16.6 months. In frontline sufferers who went on to obtain stem cell transplants, full remission and full remission with minimal pores and skin abnormality was 92%, and median total survival was not reached.
Glossary:
Full remission: disappearance of all indicators of most cancers in response to therapy.
Total survival: time from therapy begin or analysis till loss of life from any trigger.
Total response price: proportion of sufferers whose most cancers shrinks or disappears after therapy.
Length of response (DOR): size of time a therapy retains most cancers beneath management after it first responds.
Relapsed/refractory (R/R): most cancers that has returned after therapy (relapsed) or didn’t reply to prior remedy (refractory).
For sufferers with relapsed or refractory BPDCN, full remission and full remission with minimal pores and skin abnormality was 14%, with a median length of response of 9.2 months. The general response price was 35%, median total survival was 5.8 months, and 12% of sufferers had been capable of obtain a stem cell transplant.
Sufferers within the frontline group obtained a median of 5 cycles of PVEK, whereas the relapsed or refractory group obtained a median of three cycles.
“Significant improvements in most cancers analysis and therapy are taking place every single day. It is vital that these improvements attain sufferers who desperately want them, together with these with uncommon cancers who’ve restricted choices,” Roopal Thakkar, government vp, analysis and growth and chief scientific officer, AbbVie, mentioned within the information launch.
He continued, “We sit up for subsequent steps within the regulatory course of for our newest antibody-drug conjugate (ADC), our first ADC in blood most cancers, and the way it could advance therapy for these dwelling with blastic plasmacytoid dendritic cell neoplasm.”
Security was evaluated in all 84 sufferers within the CADENZA trial. The most typical facet impact was peripheral edema, occurring in 54% of sufferers and in 12% at extra extreme ranges (grade 3 [severe] or greater). Unwanted side effects led to stopping therapy in 9% of frontline sufferers and seven% of these with relapsed or refractory illness.
No instances of capillary leak syndrome or treatment-related deaths had been reported. Two sufferers (2%) skilled veno-occlusive illness of the liver after cycles 4 and eight, which resolved.
Trial Design of the Section 1/2 CADENZA Trial
Adults with BPDCN obtained PVEK as an intravenous (into the vein) infusion lasting lower than half-hour on day 1 of a 21-day cycle. The first purpose was the speed of composite full response, combining CR and CRc in frontline sufferers. Key secondary measures included length of CR and CRc, total survival, total response price, the proportion of sufferers bridged to stem cell transplant after PVEK and security and tolerability.
What’s Blastic Plasmacytoid Dendritic Cell Neoplasm? How Does PVEK Work?
BPDCN is a uncommon, aggressive blood most cancers with options of each leukemia and lymphoma. Sufferers typically develop pores and skin lesions, and the illness can unfold to the bone marrow, central nervous system, and lymph nodes, as per the discharge. First-line therapy often entails intensive chemotherapy, typically adopted by stem cell transplant, however extra and modern choices are wanted for newly recognized sufferers and people with relapsed or refractory illness.
PVEK is an antibody-drug conjugate that targets CD123, a protein overexpressed in BPDCN. This remedy delivers a potent cancer-killing payload on to cells with CD123, providing a promising method for sufferers with BPDCN and different blood cancers reminiscent of acute myeloid leukemia.
References
- “AbbVie Submits Biologics License Utility (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) – an Investigational Antibody-Drug Conjugate (ADC) to Deal with Uncommon Most cancers with Restricted Remedy Choices.” Information Launch. Abbvie. Sep 30. 2025. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6502
- “Efficacy and security of pivekimab sunirine (PVEK) in sufferers (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) within the CADENZA examine,” by Dr. Naveen Pemmaraju, et al., Journal of Scientific Oncology. https://information.abbvie.com/2025-09-30-AbbVie-Submits-Biologics-License-Utility-BLA-to-U-S-FDA-for-Pivekimab-sunirine-PVEK-an-Investigational-Antibody-Drug-Conjugate-ADC-to-Deal with-Uncommon-Most cancers-with-Restricted-Remedy-Choices
For extra information on most cancers updates, analysis and training,
